The FDA recalls a high blood pressure drug for failing to meet quality standards

The Food and Drug Administration (FDA) ordered the recall of thousands of packages of high blood pressure medications. The reason is that these drugs do not meet federal quality standards.

Specifically, the recall affects 3,528 bottles of 30 tablets from lot 12251163A and 216 bottles of 90 tablets from lot 12251163B of olmesartan medoxomil, amlodipine and hydrochlorothiazide. The company to which this order is addressed, Macleods Pharma USA, has already begun recalling them.

The FDA, which based its decision on "failure to meet dissolution specifications," urged consumers of this drug to check the bottles they purchased to see whether or not they comply with federal quality standards and whether or not they are included in the order issued.

In its statement, the agency explained that the medications were not manufactured properly to meet legal standards.

Furthermore, the FDA classified its order such that use of the affected medication "may cause adverse health effects that are temporary or medically reversible." Even so, it maintained that the likelihood of the drug's use causing serious health effects is "remote."